Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Immune-Onc to partner with University of Texas on novel cancer immunotherapy

Published 07 April 2017

Immune-Onc Therapeutics has signed an exclusive license and collaboration agreement with The University of Texas Health Science Center at Houston (“UTHealth”) and The University of Texas Southwestern Medical Center (“UTSW”), two member institutions of The University of Texas System (“UT System”).

Under the terms of the license agreement, Immune-Onc will acquire the exclusive global rights to develop and commercialize novel biotherapeutics with applications in cancer immunotherapy and other diseases.  In addition, Immune-Onc has entered into a multi-year research collaboration with UTHealth and UTSW to discover and develop a new generation of biotherapeutics that modulate the immune system.

This collaboration will leverage the Cancer Prevention & Research Institute of Texas (“CPRIT”) Therapeutic Monoclonal Antibody Lead Optimization and Development Core Facility at UTHealth to advance lead antibodies from academic laboratories, and will utilize the preclinical and clinical drug development expertise of Immune-Onc to move them to clinical trials and eventually to eligible patients.

Dr. Charlene Liao, Chief Executive Officer of Immune-Onc said: "UTHealth is a comprehensive academic health center and a valuable resource for health care education, biomedical research, and patient care.  UTSW is a world renowned academic medical center with a distinguished record of breakthrough scientific discoveries.

“Immune-Onc is very pleased to license innovative biotherapeutic candidates from UTHealth and UTSW.  We are honored to initiate this collaboration with members of the UT System that has the potential to provide new treatment options for cancer patients in the near future.”

“This is an important step in translating our therapeutic antibody from discovery to development,” said Dr. Zhiqiang An, Professor of Molecular Medicine, the Robert A. Welch Distinguished University Chair in Chemistry, and Director of the Texas Therapeutics Institute (TTI) at the Brown Foundation Institute of Molecular Medicine at UTHealth.

Dr. Bruce D. Butler, Vice President, Research and Technology at UTHealth said: “Immune-Onc has assembled a strong team of drug development experts from leading biopharmaceutical companies.

“We look forward to collaborating with Immune-Onc to bring benefits to patients.”



Source: Company Press Release